Current molecular diagnostics of breast cancer and the potential incorporation of microRNA

Christine K. Zoon, Elizabeth Q. Starker, Arianne M. Wilson, Michael R. Emmert-Buck, Steven K. Libutti, Michael A. Tangrea

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Although comprehensive molecular diagnostics and personalized medicine have sparked excitement among researchers and clinicians, they have yet to be fully incorporated into today's standard of care. This is despite the discovery of disease-related oncogenes, tumor-suppressor genes and protein biomarkers, as well as other biological anomalies related to cancer. Each year, new tests are released that could potentially supplement or surpass standard methods of diagnosis, including serum, protein and gene expression analyses. All of these novel approaches have shown great promise, but initial enthusiasm has diminished as difficulties in reproducibility, expense, standardization and proof of significance beyond current protocols have emerged. This review will focus on current and novel molecular diagnostic tools applied to breast cancer with special attention to the exciting new field of microRNA analysis.

Original languageEnglish (US)
Pages (from-to)455-466
Number of pages12
JournalExpert Review of Molecular Diagnostics
Volume9
Issue number5
DOIs
StatePublished - Jul 2009

Fingerprint

Molecular Pathology
MicroRNAs
Breast Neoplasms
Molecular Medicine
Tumor Suppressor Proteins
Precision Medicine
Standard of Care
Tumor Suppressor Genes
Oncogenes
Blood Proteins
Biomarkers
Research Personnel
Gene Expression
Neoplasms
Proteins

Keywords

  • Breast cancer
  • Microarray
  • MicroRNA
  • Molecular diagnostics
  • Predictive value
  • Prognostic value

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pathology and Forensic Medicine

Cite this

Zoon, C. K., Starker, E. Q., Wilson, A. M., Emmert-Buck, M. R., Libutti, S. K., & Tangrea, M. A. (2009). Current molecular diagnostics of breast cancer and the potential incorporation of microRNA. Expert Review of Molecular Diagnostics, 9(5), 455-466. https://doi.org/10.1586/erm.09.25

Current molecular diagnostics of breast cancer and the potential incorporation of microRNA. / Zoon, Christine K.; Starker, Elizabeth Q.; Wilson, Arianne M.; Emmert-Buck, Michael R.; Libutti, Steven K.; Tangrea, Michael A.

In: Expert Review of Molecular Diagnostics, Vol. 9, No. 5, 07.2009, p. 455-466.

Research output: Contribution to journalArticle

Zoon, CK, Starker, EQ, Wilson, AM, Emmert-Buck, MR, Libutti, SK & Tangrea, MA 2009, 'Current molecular diagnostics of breast cancer and the potential incorporation of microRNA', Expert Review of Molecular Diagnostics, vol. 9, no. 5, pp. 455-466. https://doi.org/10.1586/erm.09.25
Zoon, Christine K. ; Starker, Elizabeth Q. ; Wilson, Arianne M. ; Emmert-Buck, Michael R. ; Libutti, Steven K. ; Tangrea, Michael A. / Current molecular diagnostics of breast cancer and the potential incorporation of microRNA. In: Expert Review of Molecular Diagnostics. 2009 ; Vol. 9, No. 5. pp. 455-466.
@article{02a60aba4a2c4b7291cc85ab5091890d,
title = "Current molecular diagnostics of breast cancer and the potential incorporation of microRNA",
abstract = "Although comprehensive molecular diagnostics and personalized medicine have sparked excitement among researchers and clinicians, they have yet to be fully incorporated into today's standard of care. This is despite the discovery of disease-related oncogenes, tumor-suppressor genes and protein biomarkers, as well as other biological anomalies related to cancer. Each year, new tests are released that could potentially supplement or surpass standard methods of diagnosis, including serum, protein and gene expression analyses. All of these novel approaches have shown great promise, but initial enthusiasm has diminished as difficulties in reproducibility, expense, standardization and proof of significance beyond current protocols have emerged. This review will focus on current and novel molecular diagnostic tools applied to breast cancer with special attention to the exciting new field of microRNA analysis.",
keywords = "Breast cancer, Microarray, MicroRNA, Molecular diagnostics, Predictive value, Prognostic value",
author = "Zoon, {Christine K.} and Starker, {Elizabeth Q.} and Wilson, {Arianne M.} and Emmert-Buck, {Michael R.} and Libutti, {Steven K.} and Tangrea, {Michael A.}",
year = "2009",
month = "7",
doi = "10.1586/erm.09.25",
language = "English (US)",
volume = "9",
pages = "455--466",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "5",

}

TY - JOUR

T1 - Current molecular diagnostics of breast cancer and the potential incorporation of microRNA

AU - Zoon, Christine K.

AU - Starker, Elizabeth Q.

AU - Wilson, Arianne M.

AU - Emmert-Buck, Michael R.

AU - Libutti, Steven K.

AU - Tangrea, Michael A.

PY - 2009/7

Y1 - 2009/7

N2 - Although comprehensive molecular diagnostics and personalized medicine have sparked excitement among researchers and clinicians, they have yet to be fully incorporated into today's standard of care. This is despite the discovery of disease-related oncogenes, tumor-suppressor genes and protein biomarkers, as well as other biological anomalies related to cancer. Each year, new tests are released that could potentially supplement or surpass standard methods of diagnosis, including serum, protein and gene expression analyses. All of these novel approaches have shown great promise, but initial enthusiasm has diminished as difficulties in reproducibility, expense, standardization and proof of significance beyond current protocols have emerged. This review will focus on current and novel molecular diagnostic tools applied to breast cancer with special attention to the exciting new field of microRNA analysis.

AB - Although comprehensive molecular diagnostics and personalized medicine have sparked excitement among researchers and clinicians, they have yet to be fully incorporated into today's standard of care. This is despite the discovery of disease-related oncogenes, tumor-suppressor genes and protein biomarkers, as well as other biological anomalies related to cancer. Each year, new tests are released that could potentially supplement or surpass standard methods of diagnosis, including serum, protein and gene expression analyses. All of these novel approaches have shown great promise, but initial enthusiasm has diminished as difficulties in reproducibility, expense, standardization and proof of significance beyond current protocols have emerged. This review will focus on current and novel molecular diagnostic tools applied to breast cancer with special attention to the exciting new field of microRNA analysis.

KW - Breast cancer

KW - Microarray

KW - MicroRNA

KW - Molecular diagnostics

KW - Predictive value

KW - Prognostic value

UR - http://www.scopus.com/inward/record.url?scp=67650430027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650430027&partnerID=8YFLogxK

U2 - 10.1586/erm.09.25

DO - 10.1586/erm.09.25

M3 - Article

C2 - 19580430

AN - SCOPUS:67650430027

VL - 9

SP - 455

EP - 466

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 5

ER -